Skip to main content
. Author manuscript; available in PMC: 2019 Jun 9.
Published in final edited form as: Nature. 2018 Nov 21;563(7732):559–563. doi: 10.1038/s41586-018-0702-1

Extended Data Fig. 5 |. PCDH1 ECl-specific mAb 3305 blocks ANDV and SNV entry into primary HPMECs.

Extended Data Fig. 5 |

HPMECs were preincubated with mAb 3305 or with human IgG control (Ctrl) (0–100 μg ml–1, 0–680 nM, in serial threefold dilutions), and then exposed to the indicated rVSVs Gn/Gc glycoproteins at a MOI of 0.2 IU per cell. Infected cells were scored at 9 hpi. One hundred per cent relative infectivity corresponds to 15–20% infected cells. Averages ± s.d.: three experiments; no-mAb samples (‘0’), n = 10 for ANDV and HTNV, n = 3 for SNV; mAb-treated samples, n = 5 for ANDV and HTNV, n = 3 for SNV. mAb 3305 versus control mAb, two-way ANO VA with Dunnett’s test: ns, P > 0.05; ****P < 0.0001.